MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$26,233,000
EPS
-$0.34
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Collaboration revenue
-
0
0
0
Research and development
12,444,000
14,084,000
15,416,000
14,296,000
General and administrative
7,462,000
8,102,000
7,277,000
7,562,000
Impairment of long-lived assets
5,086,000
-
-
-
Restructuring expenses
4,318,000
0
0
0
Total operating expenses
29,310,000
22,186,000
22,693,000
21,858,000
Loss from operations
-29,310,000
-22,186,000
-22,693,000
-21,858,000
Other income, net
3,131,000
3,295,000
2,359,000
2,263,000
Net loss
-26,179,000
-18,891,000
-20,334,000
-19,595,000
Unrealized (gain) loss on marketable securities
-54,000
-687,000
-115,000
159,000
Total other comprehensive (gain) loss
-54,000
-687,000
-115,000
159,000
Comprehensive loss
-26,233,000
-19,578,000
-20,449,000
-19,436,000
Basic EPS
-0.34
-0.25
0.109
-0.31
Diluted EPS
-0.34
-0.25
0.109
-0.31
Basic Average Shares
76,264,000
76,215,000
-187,366,580
62,597,000
Diluted Average Shares
76,264,000
76,215,000
-187,366,580
62,597,000
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$26,233,000
Net loss
-$26,179,000
(-51.36%↓ Y/Y)
Total other
comprehensive (gain) loss
-$54,000
Other income, net
$3,131,000
(24.30%↑ Y/Y)
Loss from operations
-$29,310,000
(-47.92%↓ Y/Y)
Unrealized (gain) loss on
marketable securities
-$54,000
Total operating
expenses
$29,310,000
(47.92%↑ Y/Y)
Research and development
$12,444,000
(-4.18%↓ Y/Y)
General and
administrative
$7,462,000
(9.29%↑ Y/Y)
Impairment of long-lived
assets
$5,086,000
Restructuring expenses
$4,318,000
Buy us a coffee
Fulcrum Therapeutics, Inc. (FULC)
Fulcrum Therapeutics, Inc. (FULC)